"Designing Growth Strategies is in our DNA"

Fabrys Disease Treatment Market Size, Share and Global Trend By Treatment (Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Chaperone Treatment, Others), By Route of Administration (Oral, Intravenous, Others) and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI101007 | Status : Ongoing

 

KEY MARKET INSIGHTS

Fabry’s disease is a rare X-linked lysosomal storage disorder with a deficiency of alpha-galactosidase enzyme leading to progressive organ dysfunction. Fabry’s disease is caused due to the abnormal accumulation of a specific fatty matter called globotriaosylceramide in multiple tissues of the body, including skin, eyes, brain, kidney, gastrointestinal system, heart, and central nervous system.

According to the U.S. National Library of Medicine, Fabry’s disease affects an estimated 1 in 40,000 to 60,000 males. Patients with Fabry’s disease suffer from severe pain of extremities, heart disorder, kidney failure, disabling gastrointestinal symptoms and stroke.

To gain extensive insights into the market, Request for Customization


Increasing prevalence Fabry's diseases coupled with increased adoption of novel therapies such as chaperone treatment is one of the major driving factors for the growth of the global Fabry's disease treatment market. Additionally, extensive R&D activities and potential approval of promising pipeline products, including enzyme replacement therapies and substrate reduction therapies are projected to escalate the growth of the global Fabry’s disease treatment market during the forecast period.

Side effects associated with the treatment options and lack of diagnostic resources in emerging countries leading to a lower rate of diagnosis in these countries are some of the factors restraining the growth of the global Fabry's disease treatment market.

Key Players Covered


Some of the major companies that are present in the global Fabry's disease treatment market is Genzyme Corporation, Shire, Amicus Therapeutics, Inc., ISU ABXIS, JCR Pharmaceuticals Co., Ltd., Protalix, Idorsia Pharmaceuticals Ltd, AVROBIO, Inc., Biosidus S.A., Neuraltus Pharmaceuticals, Inc., and others.

SEGMENTATION 






















SEGMENTATION


 DETAILS


By Treatment


· Enzyme Replacement Therapy (ERT)

· Substrate Reduction Therapy (SRT)

· Chaperone Treatment

· Others


By Route of Administration


· Oral

· Intravenous

· Others


By Geography


· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


 

In 2018, among treatment, enzyme replacement therapy dominated the global Fabry's disease treatment market due to the massive sales of Fabrazyme and Replagal and approvals of promising pipeline candidates. This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights



  • Fabry’s Disease by Key Countries

  • Advancements in Research & Development of Treatment Options

  • Pipeline analysis

  • Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions


Regional Analysis


North America dominated the global Fabry's disease treatment market in 2018. Increasing adoption of novel therapies and favorable reimbursement policies are some of the factors driving the growth of the Fabry's disease treatment market in the region. Also, favorable governmental policies encouraging pharmaceutical companies to increase research and developments investments in the field of rare diseases is anticipated to drive the growth of Fabry's disease treatment market in North America.

Key Industry Developments



  • In August 2018, Amicus Therapeutics, received U.S. Food and Drug Administration (FDA) approval for the Galafold (migalastat) 123 mg capsules. Galafold is an oral, precision medicine for the treatment of adults with Fabry disease.
  • In July 2018, CHIESI Farmaceutici S.p.A., received development and sales rights to the therapy in all countries outside the U.S. for PRX-102 an investigative therapy for the treatment of the Fabry’s disease from Protalix Biotherapeutics.




  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Johnson
abbvie
Lek
3M
Ansell

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X